



ASX/Media Release

3 April 2019

Acrux announces patent litigation settlement for generic version of Jublia® Topical Solution 10%

Melbourne, Australia; 3 April 2019: Acrux Limited (ASX:ACR, “Acrux”) is pleased to announce that it has settled its Hatch-Waxman patent litigation relating to its first-to-file Abbreviated New Drug Application (ANDA) for the generic equivalent to Jublia® (efinaconazole) Topical Solution 10% brought by Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland Ltd., Dow Pharmaceuticals Sciences, Inc. (subsidiaries of Bausch Health Companies Inc.), and Kaken Pharmaceuticals Co., Ltd. Terms of the settlement are confidential. This settlement has no financial impact on Acrux.

Acrux CEO and Managing Director, Michael Kotsanis said:

“This settlement is a positive stride forward for our growing pipeline. Our R&D and product development teams continue to achieve their operational targets. This product is one of 14 generic topical products in our pipeline which are progressing to commercialisation.”

Acrux’s generic equivalent to Jublia® is currently under review by the FDA.

For more information, please contact:

General enquiries

Michael Kotsanis
Acrux Limited
CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

Investor enquiries

Anthony England
Vesparum Capital

P: +61 3 8582 4800

E: acrux@vesparum.com

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of topical and dermatological generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au